Related Experiment Videos
ZD1839 (IRESSA): a selective EGFR-TK inhibitor
Malcolm Ranson1, Was Mansoor, Gordon Jayson
1Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, UK. malcolm.ranson@amn.ac.uk
Expert Review of Anticancer Therapy
|July 13, 2002
Abstract:
The recent development of highly selective, target-based cancer therapeutics, such as ZD1839 has resulted from a greater understanding of tumor biology. Amongst the most promising of new target-based agents are inhibitors of the epidermal growth factor receptor. ZD 1839 is a potent, selective epidermal growth factor receptor tyrosine kinase inhibitor that has demonstrated promising results in early clinical trials.